Innoviva advised the Board that it wished to designate Jules Haimovitz to replace Dr. Schlesinger as one of Innoviva’s designated directors on the Board. On April 1, 2021, the Board appointed Mr. Haimovitz as one of Innoviva’s designated directors on the Board, to serve until the Company’s next annual meeting of the Company’s stockholders. The Board also voted that Dr. Schlesinger remain on the Board though she will not be a director designated by Innoviva. Dr. Kostas will continue to serve as a designated director of Innoviva.